Tumor cells (ARP1 and K562) after Heparinase III treatment (ARP1HSPG- and K562HSPG-) and MM cells after knock-down of CD138 (siRNA) were co-cultured in parallel with CB-NK, adding exogenous recombinant H2AZ and H4 at a non-toxic dose (Fig. 6m). The gene discussed is SDC1; the disease is Miyoshi myopathy.